Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates
- PMID: 27493269
- DOI: "V体育2025版" 10.2967/jnumed.116.178665
"V体育安卓版" Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates
Abstract
The tyrosine kinase inhibitor erlotinib poorly penetrates the blood-brain barrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), thereby limiting its utility in the treatment of non-small cell lung cancer metastases in the brain. Pharmacologic strategies to inhibit ABCB1/ABCG2-mediated efflux transport at the BBB have been successfully developed in rodents, but it remains unclear whether these can be translated to humans given the pronounced species differences in ABCG2/ABCB1 expression ratios at the BBB. We assessed the efficacy of two different ABCB1/ABCG2 inhibitors to enhance brain distribution of 11C-erlotinib in nonhuman primates as a model of the human BBB. VSports手机版.
Methods: Papio anubis baboons underwent PET scans of the brain after intravenous injection of 11C-erlotinib under baseline conditions (n = 4) and during intravenous infusion of high-dose erlotinib (10 mg/kg/h, n = 4) or elacridar (12 mg/kg/h, n = 3) V体育安卓版. .
Results: Under baseline conditions, 11C-erlotinib distribution to the brain (total volume of distribution [VT], 0. 22 ± 0. 015 mL/cm3) was markedly lower than its distribution to muscle tissue surrounding the skull (VT, 0. 86 ± 0. 10 mL/cm3). Elacridar infusion resulted in a 3. 5 ± 0 V体育ios版. 9-fold increase in 11C-erlotinib distribution to the brain (VT, 0. 81 ± 0. 21 mL/cm3, P < 0. 01), reaching levels comparable to those in muscle tissue, without changing 11C-erlotinib plasma pharmacokinetics. During high-dose erlotinib infusion, 11C-erlotinib brain distribution was also significantly (1. 7 ± 0. 2-fold) increased (VT, 0. 38 ± 0. 033 mL/cm3, P < 0. 05), with a concomitant increase in 11C-erlotinib plasma exposure. .
Conclusion: We successfully implemented ABCB1/ABCG2 inhibition protocols in nonhuman primates resulting in pronounced increases in brain distribution of 11C-erlotinib. For patients with brain tumors, such inhibition protocols may ultimately be applied to create more effective treatments using drugs that undergo efflux transport at the BBB VSports最新版本. .
Keywords: P-glycoprotein; blood–brain barrier; brain metastasis; breast cancer resistance protein; erlotinib V体育平台登录. .
© 2017 by the Society of Nuclear Medicine and Molecular Imaging VSports注册入口. .
MeSH terms
- Actions (VSports)
- Actions (VSports在线直播)
- Actions (V体育平台登录)
- "VSports" Actions
- VSports手机版 - Actions
- Actions (V体育安卓版)
- VSports app下载 - Actions
- "V体育官网" Actions
- "V体育官网入口" Actions
- VSports最新版本 - Actions
Substances
- "VSports最新版本" Actions
- VSports最新版本 - Actions
- "V体育官网入口" Actions
- "VSports手机版" Actions
- "VSports在线直播" Actions
- "V体育官网" Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources